Atrial fibrillation (AF): treatment
Evidence-based neurology checklist on atrial fibrillation (af): treatment: Anticoagulation with vitamin K antagonists Vitamin K antagonists are indicated for paroxysmal or permanent AF Low molecular weight heparin (LMWH) bridging therapy is indicated if the risk of stroke is high Anticoagulation…
Anticoagulation with vitamin K antagonists
- Vitamin K antagonists are indicated for paroxysmal or permanent AF
- Low molecular weight heparin (LMWH) bridging therapy is indicated if the risk of stroke is high
- Anticoagulation is usually instituted within 14 days of stroke
- It may be delayed if the infarct is large or complicated with haemorrhagic transformation
- It may also be delayed if there is uncontrolled hypertension or a bleeding tendency
Anticoagulation with new oral anticoagulants (NOACs)
Antiplatelets
Rate control: options
Rhythm control
Surgical ablation of left atrial appendage: options
References
- Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:2160-2236.
- Bal S, Ojha P, Hill MD. Stroke prevention treatment of patients with atrial fibrillation: old and new. Curr Neurol Neurosci Rep 2011; 11:15-27.
- Prystowsky EN. Management of atrial fibrillation: therapeutic and clinical decisions. Am J Cardiol 2000; 85:3D-11D.
- Kreuzer J. Update on anti-coagulation in atrial fibrillation. Q J Med 2011; 104:747-760.
